Theravance officer plans sale of 13,314 shares

Theravance Biopharma, Inc. (TBPH) has an officer, Rhonda Farnum, filing a notice of proposed sale under Rule 144 for 13,314 shares of common stock.

Rhea-AI Filing Summary

Theravance Biopharma, Inc. (TBPH) has an officer, Rhonda Farnum, filing a notice of proposed sale under Rule 144 for 13,314 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $226,793.34 as of the notice.

The shares were acquired from the issuer as vested restricted stock and Performance Shares during the period from August 20, 2023 through February 20, 2025. Shares outstanding for the class listed in the notice total 51,918,754.

Key Figures

Shares proposed to be sold: 13,314 shares Aggregate market value: $226,793.34 Shares outstanding for class: 51,918,754 shares +2 more

5 metrics

Shares proposed to be sold 13,314 shares Common stock covered by the Rule 144 notice

Aggregate market value $226,793.34 Value of 13,314 shares proposed for sale under Rule 144

Shares outstanding for class 51,918,754 shares Outstanding Theravance Biopharma common stock for the class listed

Acquisition period for shares August 20, 2023 to February 20, 2025 Period during which restricted stock and Performance Shares vested

Planned sale date September 15, 2026 Approximate date of sale listed for the Rule 144 transaction

Key Terms

Rule 144, restricted stock, Performance Shares, aggregate market value

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock financial

"The securities to be sold were acquired upon the vesting of restricted stock"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Performance Shares financial

"The securities to be sold were acquired upon the vesting of restricted stock and Performance Shares"

Performance shares are a type of company stock given to executives or employees that only become theirs if the company meets specific goals, like hitting certain profits or growth targets. They motivate leaders to work toward the company’s success, because their additional shares depend on achieving these results.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 13314 | 226793.34 |"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for Theravance Biopharma (TBPH)?

The filing reports that officer Rhonda Farnum plans to sell 13,314 shares of Theravance Biopharma common stock under Rule 144 through Morgan Stanley Smith Barney LLC. It is a notice of a potential sale, not confirmation that the sale has occurred.

How many TBPH shares are proposed to be sold under this Form 144?

The notice covers a proposed sale of 13,314 shares of Theravance Biopharma common stock. The filing lists an aggregate market value of $226,793.34 for these shares as of the date of the notice.

What is the source of the Theravance Biopharma (TBPH) shares being sold?

The shares were acquired from the issuer upon the vesting of restricted stock and Performance Shares during the period from August 20, 2023 through February 20, 2025, as disclosed in the remarks section.

On which exchange are the TBPH shares in this Form 144 expected to be sold?

The notice states that the common stock covered by the Form 144 may be sold on NASDAQ. Morgan Stanley Smith Barney LLC is listed as the broker handling the transaction.

How many Theravance Biopharma (TBPH) shares are outstanding for this class in the notice?

The Form 144 indicates that 51,918,754 shares of Theravance Biopharma common stock are outstanding for the class referenced. This figure provides context and is not the amount being sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:08 PM Accepted by SEC EDGAR 09/15/2026 - 04:07 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001898490
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	THERAVANCE BIOPHARMA, INC.
SEC File Number	001-36033
Address of Issuer	901 Gateway Boulevard South San Francisco CALIFORNIA 94080
Phone	650-808-6000
Name of Person for Whose Account the Securities are To Be Sold	RHONDA FARNUM
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	13314	226793.34	51918754	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/20/2023	Performance and Restricted Stock	ISSUER			13314	08/20/2023	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock and Performance Shares during the period of 08/20/2023 through 02/20/2025.
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/03/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Rhonda Freeman Farnum
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)